vimarsana.com
Home
Live Updates
Immutep Quarterly Activities Report Q2 FY24 : vimarsana.com
Immutep Quarterly Activities Report Q2 FY24
Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer patients expressing PD-L1...
Related Keywords
France ,
Sydney ,
New South Wales ,
Australia ,
Germany ,
Poland ,
Monash ,
South Australia ,
Polish ,
German ,
French ,
Australian ,
Chris Basta ,
Frederic Triebel ,
Jamie Rossjohn ,
Corporate Communications ,
Korean Intellectual Property Office ,
Merck Kga ,
Committee For Medicinal Products Human Use ,
Data Monitoring Committee ,
Monash University ,
Immutep Limited ,
Globenewswire Inc ,
Nasdaq ,
Merck Kgaa ,
Overall Survival ,
Overall Response Rate ,
Combined Positive Score ,
Integrated Phase ,
Metastatic Breast ,
Medicinal Products ,
Human Use ,
Disease Control Rate ,
Soft Tissue ,
Professor Jamie Rossjohn ,
Korean Intellectual Property ,
Australian Federal Government ,
French Government ,
Related Parties ,
Non Executive Director ,
Executive Director ,
Lymphocyte Activation ,
Investor Relations ,
Markets ,
vimarsana.com © 2020. All Rights Reserved.